Company intelligence / Profile preview
Bowen Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Bowen Therapeutics is developing therapeutic vaccines for cancer and infectious diseases using advanced immunization techniques and proprietary adjuvants. Their lead program includes a novel hexavalent recombinant protein vaccine against monkeypox virus that has shown promising preclinical results in generating neutralizing antibodies. The company also provides contract research services in recombinant proteins and antibodies, with ongoing collaborations at UMASS Medical School and partnerships with Chinese CFDA-accredited institutions for preclinical evaluation.
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Recombinant proteinVaccineMonoclonal antibody
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Bowen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bowen Therapeutics.